Details of the Drug Combination

General Information of Drug Combination (ID: DCQUQGJ)

Drug Combination Name
Itopride Sulpiride
Indication
Disease Entry Status REF
Dyspepsia Phase 1 [1]
Component Drugs Itopride   DM7MLTR Sulpiride   DMF54ZG
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Itopride Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Dimethylaniline oxidase 3 (FMO3) DEP76YL FMO3_HUMAN Metabolism [3]
------------------------------------------------------------------------------------
Itopride Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Decreases Activity [4]
------------------------------------------------------------------------------------
Indication(s) of Sulpiride
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [2]
Sulpiride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [5]
------------------------------------------------------------------------------------
Sulpiride Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Sulpiride Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Affects Binding [7]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Increases Abundance [8]
Insulin (INS) OTZ85PDU INS_HUMAN Increases Expression [9]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Transport [10]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Increases Uptake [10]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Transport [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 ClinicalTrials.gov (NCT04697641) Helicobacter Pylori Eradication in Functional Dyspepsia
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 960).
3 Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharm Drug Dispos. 2017 Sep;38(6):389-393.
4 Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase. Toxicol Lett. 2015 Feb 3;232(3):557-65.
5 The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914.
6 Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. Biol Pharm Bull. 2002 Oct;25(10):1345-50.
7 Positron emission tomography measurement of dopamine D? receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010 Sep;71(9):1131-7. doi: 10.4088/JCP.08m04307yel. Epub 2010 Feb 23.
8 D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men. J Clin Endocrinol Metab. 1987 Aug;65(2):368-9. doi: 10.1210/jcem-65-2-368.
9 Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006 Jul;186(4):572-8. doi: 10.1007/s00213-006-0384-5. Epub 2006 Apr 7.
10 Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.